News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,154 Results
Type
Article (13864)
Company Profile (294)
Press Release (245996)
Section
Business (79323)
Career Advice (148)
Deals (13179)
Drug Delivery (32)
Drug Development (50282)
Employer Resources (31)
FDA (5669)
Job Trends (5111)
News (144056)
Policy (10015)
Tag
Academia (901)
Alliances (21465)
Alzheimer's disease (734)
Approvals (5643)
Artificial intelligence (62)
Bankruptcy (97)
Best Places to Work (4496)
Biotechnology (242)
Breast cancer (64)
Cancer (684)
Cardiovascular disease (62)
Career advice (129)
CAR-T (55)
Cell therapy (174)
Clinical research (39781)
Collaboration (233)
Compensation (95)
COVID-19 (1002)
C-suite (66)
Cystic fibrosis (66)
Data (780)
Diabetes (73)
Diagnostics (1199)
Earnings (28974)
Events (46819)
Executive appointments (185)
FDA (5954)
Funding (239)
Gene editing (55)
Gene therapy (145)
GLP-1 (299)
Government (1064)
Healthcare (6532)
Infectious disease (1036)
Inflammatory bowel disease (94)
IPO (7175)
Job creations (859)
Job search strategy (125)
Layoffs (184)
Legal (1373)
Lung cancer (110)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6099)
Metabolic disorders (222)
Neuroscience (937)
NextGen Class of 2024 (1999)
Non-profit (843)
Northern California (938)
Obesity (122)
Opinion (91)
Parkinson's disease (60)
Patents (51)
People (24959)
Pharmaceutical (49)
Phase I (13990)
Phase II (18503)
Phase III (11730)
Pipeline (318)
Postmarket research (846)
Preclinical (5919)
Radiopharmaceuticals (204)
Rare diseases (166)
Real estate (1409)
Regulatory (8201)
Research institute (930)
Southern California (857)
Startups (1963)
United States (7522)
Vaccines (159)
Weight loss (76)
Date
Today (96)
Last 7 days (582)
Last 30 days (2275)
Last 365 days (20679)
2024 (18877)
2023 (22412)
2022 (26825)
2021 (27807)
2020 (23358)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16822)
Australia (2835)
California (2123)
Canada (704)
China (159)
Colorado (79)
Connecticut (84)
Europe (36225)
Florida (221)
Georgia (62)
Illinois (125)
Indiana (54)
Kansas (55)
Maryland (298)
Massachusetts (1685)
Michigan (48)
Minnesota (93)
New Jersey (537)
New York (603)
North Carolina (398)
Northern California (938)
Ohio (78)
Pennsylvania (424)
South America (207)
Southern California (857)
Texas (221)
Washington State (216)
260,154 Results for "vivet therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
November 14, 2024
·
7 min read
Press Releases
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
October 22, 2024
·
8 min read
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress.
October 23, 2023
·
3 min read
Business
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder.
September 23, 2020
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2
April 12, 2021
·
7 min read
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
Vivet Therapeutics today announced that new data regarding VTX-803, Vivet’s AAV-based gene therapy in development for the treatment of PFIC3, will be presented during the ASGCT 24th Annual Meeting, May 11 - 14, 2021.
May 10, 2021
·
5 min read
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation
Vivet Therapeutics announced that both the Food and Drug Administration and the European Commission have granted Orphan Drug Designation for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3.
June 1, 2020
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
1 of 26,016
Next